Molecular Cancer Therapeutics CTRC-AACR San Antonio Breast Cancer Symposium
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Scott, K. A.
Right arrow Articles by Balkwill, F. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Scott, K. A.
Right arrow Articles by Balkwill, F. R.
Vol. 2, 445-451, May 2003     Molecular Cancer Therapeutics
© 2003 American Association for Cancer Research

An Anti-Tumor Necrosis Factor-{alpha} Antibody Inhibits the Development of Experimental Skin Tumors

Kate A. Scott1,2, Robert J. Moore1, Caroline H. Arnott1, Nick East, Richard G. Thompson, Bernard J. Scallon, David J. Shealy and Frances R. Balkwill

Cancer Research UK Translational Oncology Laboratory, John Vane Science Centre, Barts & The London, Queen Mary’s School of Medicine and Dentistry, London EC1M 6BQ, United Kingdom [K. A. S., R. J. M., C. H. A., N. E., R. G. T., F. R. B.], and Centocor, Malvern, Pennsylvania 19355 [B. J. S., D. J. S.]

2 To whom requests for reprints should be addressed, at Cancer Research UK Translational Oncology Laboratory, Barts & The London, Queen Mary’s School of Medicine and Dentistry, 3rd Floor, John Vane Science Centre, Charterhouse Square, London EC1M 6BQ, United Kingdom. Phone: 44-207-882-5797; Fax: 44-207-882-6110; E-mail: kate.scott{at}cancer.org.uk

The proinflammatory cytokine tumor necrosis factor-{alpha} (TNF-{alpha}) was originally considered to have activity against malignant disease. However, recent studies suggest TNF-{alpha} may also act as an endogenous tumor promoter. In the present work, mice deficient in TNF-{alpha} either genetically (TNF-{alpha}-/-) or after blockade with a neutralizing antibody (cV1q) were used to investigate the role of TNF-{alpha} in skin tumor development. Papillomas were induced in wild-type (wt) mice after treatment of skin with the initiating agent 9,10-dimethyl-1,2-benzanthracene followed by promotion with 12-O-tetradecanoylphorbol-13-acetate (TPA) for 15 weeks. TNF-{alpha}-/- mice were resistant to papilloma development when compared with wt mice on C57Bl/6J, 129/SvEv, and BALB/c genetic backgrounds. Primary murine keratinocytes (newborn keratinocytes) and skin homogenates were used to characterize TPA-stimulated TNF-{alpha} expression. TPA induced TNF-{alpha} protein in newborn keratinocytes in vitro and epidermis in vivo. Neutralization of TNF-{alpha} protein with cV1q in vivo for 0–15 weeks of promotion significantly decreased skin tumor development after 9,10-dimethyl-1,2-benzanthracene/TPA treatment. cV1q treatment during the early stages of tumor promotion (0–6 weeks) was equally effective. These data suggest that early induction of TNF-{alpha} is critical for skin tumor promotion. cV1q also reduced TPA-stimulated expression of matrix metalloproteinase 9 and granulocyte macrophage colony-stimulating factor, proteins that are differentially regulated in wt and TNF-{alpha}-/- epidermis. Treatment of the 410.4 transplantable breast carcinoma with cV1q reduced tumor growth in vivo, illustrating that inhibition of tumor growth through neutralization of TNF-{alpha} is not limited to skin carcinogenesis. These results provide further evidence for procancer actions of TNF-{alpha} and give some rationale for use of TNF-{alpha} antagonists in cancer prevention and treatment.




This article has been cited by other articles:


Home page
Cancer Res.Home page
Y.-S. Lee, K.-H. Lim, X. Guo, Y. Kawaguchi, Y. Gao, T. Barrientos, P. Ordentlich, X.-F. Wang, C. M. Counter, and T.-P. Yao
The Cytoplasmic Deacetylase HDAC6 Is Required for Efficient Oncogenic Tumorigenesis
Cancer Res., September 15, 2008; 68(18): 7561 - 7569.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
L. Tonnetti, S. Netzel-Arnett, G. A. Darnell, T. Hayes, M. S. Buzza, I. E. Anglin, A. Suhrbier, and T. M. Antalis
SerpinB2 Protection of Retinoblastoma Protein from Calpain Enhances Tumor Cell Survival
Cancer Res., July 15, 2008; 68(14): 5648 - 5657.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
W. Ouyang, Y. Hu, J. Li, M. Ding, Y. Lu, D. Zhang, Y. Yan, L. Song, Q. Qu, D. Desai, et al.
Direct evidence for the critical role of NFAT3 in benzo[a]pyrene diol-epoxide-induced cell transformation through mediation of inflammatory cytokine TNF induction in mouse epidermal Cl41 cells
Carcinogenesis, October 1, 2007; 28(10): 2218 - 2226.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. Ding, X. Zhang, J. Li, L. Song, W. Ouyang, D. Zhang, C. Xue, M. Costa, J. A. Melendez, and C. Huang
Nickel Compounds Render Anti-apoptotic Effect to Human Bronchial Epithelial Beas-2B Cells by Induction of Cyclooxygenase-2 through an IKKbeta/p65-dependent and IKK{alpha}- and p50-independent Pathway
J. Biol. Chem., December 22, 2006; 281(51): 39022 - 39032.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
B. Yan, H. Wang, Z. N. Rabbani, Y. Zhao, W. Li, Y. Yuan, F. Li, M. W. Dewhirst, and C.-Y. Li
Tumor Necrosis Factor-{alpha} Is a Potent Endogenous Mutagen that Promotes Cellular Transformation
Cancer Res., December 15, 2006; 66(24): 11565 - 11570.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
J. Chen, X. Cheng, M. Merched-Sauvage, C. Caulin, D. R. Roop, and P. J. Koch
An unexpected role for keratin 10 end domains in susceptibility to skin cancer
J. Cell Sci., December 15, 2006; 119(24): 5067 - 5076.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
N. Devoogdt, H. Revets, A. Kindt, Y. Q. Liu, P. De Baetselier, and G. H. Ghassabeh
The Tumor-Promoting Effect of TNF-{alpha} Involves the Induction of Secretory Leukocyte Protease Inhibitor
J. Immunol., December 1, 2006; 177(11): 8046 - 8052.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. Ding, J. Li, C. Xue, K. Wu, W. Ouyang, D. Zhang, Y. Yan, and C. Huang
Cyclooxygenase-2 Induction by Arsenite Is through a Nuclear Factor of Activated T-cell-dependent Pathway and Plays an Antiapoptotic Role in Beas-2B Cells
J. Biol. Chem., August 25, 2006; 281(34): 24405 - 24413.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
Y. Yan, J. Li, W. Ouyang, Q. Ma, Y. Hu, D. Zhang, J. Ding, Q. Qu, K. Subbaramaiah, and C. Huang
NFAT3 is specifically required for TNF-{alpha}-induced cyclooxygenase-2 (COX-2) expression and transformation of Cl41 cells
J. Cell Sci., July 15, 2006; 119(14): 2985 - 2994.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
T. Hagemann, J. Wilson, F. Burke, H. Kulbe, N. F. Li, A. Pluddemann, K. Charles, S. Gordon, and F. R. Balkwill
Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype.
J. Immunol., April 15, 2006; 176(8): 5023 - 5032.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
P. W. Szlosarek, M. J. Grimshaw, H. Kulbe, J. L. Wilson, G. D. Wilbanks, F. Burke, and F. R. Balkwill
Expression and regulation of tumor necrosis factor {alpha} in normal and malignant ovarian epithelium.
Mol. Cancer Ther., February 1, 2006; 5(2): 382 - 390.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Cell Mol. Bio.Home page
S. D. Tachado, J. Zhang, J. Zhu, N. Patel, and H. Koziel
HIV Impairs TNF-{alpha} Release in Response to Toll-Like Receptor 4 Stimulation in Human Macrophages In Vitro
Am. J. Respir. Cell Mol. Biol., December 1, 2005; 33(6): 610 - 621.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
R. Montesano, P. Soulie, J. A. Eble, and F. Carrozzino
Tumour necrosis factor {alpha} confers an invasive, transformed phenotype on mammary epithelial cells
J. Cell Sci., August 1, 2005; 118(15): 3487 - 3500.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
B. Shan, Y. Zhuo, D. Chin, C. A. Morris, G. F. Morris, and J. A. Lasky
Cyclin-dependent Kinase 9 Is Required for Tumor Necrosis Factor-{alpha}-stimulated Matrix Metalloproteinase-9 Expression in Human Lung Adenocarcinoma Cells
J. Biol. Chem., January 14, 2005; 280(2): 1103 - 1111.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
K. E. Peterson, S. Hughes, D. E. Dimcheff, K. Wehrly, and B. Chesebro
Separate Sequences in a Murine Retroviral Envelope Protein Mediate Neuropathogenesis by Complementary Mechanisms with Differing Requirements for Tumor Necrosis Factor Alpha
J. Virol., December 1, 2004; 78(23): 13104 - 13112.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
C. J. Nicol, M. Yoon, J. M. Ward, M. Yamashita, K. Fukamachi, J. M. Peters, and F. J. Gonzalez
PPAR{gamma} influences susceptibility to DMBA-induced mammary, ovarian and skin carcinogenesis
Carcinogenesis, September 1, 2004; 25(9): 1747 - 1755.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.